
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc. is positioned favorably within the lucrative biopharmaceutical market, particularly following the significant revenue generation of approximately $56 billion from mRNA COVID-19 vaccines in 2022. The company's lead candidate, VYD2311, is currently undergoing a Phase 3 trial program called REVOLUTION, which, if successful, could substantially expand its target market and potentially validate the efficacy of monoclonal antibodies over existing mRNA vaccines. Additionally, continued advancement in the development of VYD2311 and other monoclonal antibody candidates underscores Invivyd's commitment to addressing serious viral infections, which may enhance its competitive standing in the rapidly evolving therapeutic landscape.
Bears say
The negative outlook on Invivyd Inc.'s stock is primarily driven by the substantial decrease in the efficacy of its lead product, PEMGARDA, against the omicron variant, which was found to be approximately 200-fold lower in the STAMP trial. Additionally, the diminished protective levels of mRNA vaccines in vulnerable populations, such as the elderly and immunocompromised, further reduce the commercial viability of Invivyd's mAb therapies in addressing the needs of these key demographics. Compounding these challenges, the ongoing decline in COVID-19 vaccination rates, alongside decreasing influenza vaccination rates, significantly shrinks the overall market opportunity for the company.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares